EAACI Biologicals Guidelines—Recommendations for severe asthma

…, A Papi, HS Park, L Perez de Llano… - Allergy, 2021 - Wiley Online Library
… Luis Pérez de Llano … Luis Pérez de Llano … >150 cells/μL meeting the criteria for atopy (by
Phadiatop test) and serum IgE concentration of 30 to 700 kU/L (US) and 30 to 1500 kU/L (EU). …

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic …

…, A Papi, HS Park, L Pérez de Llano… - Allergy, 2020 - Wiley Online Library
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized
phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, …

Defining a severe asthma super-responder: findings from a Delphi process

…, LP Boulet, L Perez-de-Llano, L Ricciardi… - The Journal of Allergy …, 2021 - Elsevier
Background Clinicians are increasingly recognizing severe asthma patients in whom biologics
and other add-on therapies lead to dramatic improvement. Currently, there is no agreed-…

[HTML][HTML] Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome

…, LA Pérez de Llano, S De la Fuente Sanchez… - PLoS …, 2015 - journals.plos.org
Aim To study whether mortality and cardiovascular morbidity differ in non-invasive ventilation
(NIV)-treated patients with severe obesity-hypoventilation syndrome (OHS) as compared …

Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study

…, WC Moore, LA Perez-de-Llano… - Journal of asthma …, 2022 - Taylor & Francis
Introduction International registries provide opportunities to describe use of biologics for
treating severe asthma in current clinical practice. Our aims were to describe real-life global …

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines …

…, A Papi, HS Park, L Pérez de Llano… - Allergy, 2020 - Wiley Online Library
… For FEV 1 the GDG panel recommended a MID of 0.20 litres (L). … Mean morning PEFR
change from baseline was 8.5 L/min in the omalizumab group, and 1 L/min in the placebo group at …

Omalizumab therapy in severe asthma: experience from the Spanish registry—some new approaches

MDC Vennera, L Perez de Llano, S Bardagí… - Journal of …, 2012 - Taylor & Francis
Objective. The efficacy of omalizumab in severe asthma has been widely demonstrated. The
main objective of this study was to evaluate the efficacy and tolerability of omalizumab in a …

Haemodynamic effects of non‐invasive ventilation in patients with obesity‐hypoventilation syndrome

…, R Golpe, LA PÉREZDELLANO… - …, 2012 - Wiley Online Library
Background and objective: Although it has been reported that pulmonary hypertension is
more frequent in patients with obesity‐hypoventilation syndrome than in patients with ‘pure’ …

Short and long-term impact of COVID-19 infection on previous respiratory diseases

…, R Otero-Candelera, L Perez-de Llano… - Archivos de …, 2022 - Elsevier
de diversas maneras y en un espectro de gravedades de la enfermedad, dependiendo del
sistema inmunitario de … información sobre el impacto de la enfermedad por COVID-19 en las …

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in …

…, A Papi, HS Park, L Pérez de Llano… - Allergy, 2020 - Wiley Online Library
Dupilumab, a fully human monoclonal antibody against interleukin‐4 receptor α, is approved
as add‐on maintenance treatment for inadequately controlled type 2 severe asthma. This …